Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections (Q34560321)

3 August 2017

1 reference

title

Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections (English)

1 reference

3 August 2017

Gram-negative bacteria

0 references

colistimethate

1 reference

1 reference

59064

colistimethate sodium

1 reference

1 reference

colistin A sodium methanesulfonate

37943

1 reference

colistin b hydrogen methanesulfonate

59663

1 reference

colistin B sodium methanesulfonate

59671

1 reference

1 reference

1 reference

59669

multiple drug resistance

1 reference

inferred from title

antibiotic resistance

1 reference

Robert W Milne

4

0 references

Roger L Nation

Roger L Nation

2

0 references

Jian Li

Jian Li

1

0 references

David L Paterson

David L Paterson

7

0 references

Craig R Rayner

6

Craig R Rayner

1 reference

3 August 2017

3

John D Turnidge

1 reference

3 August 2017

5

Kingsley Coulthard

1 reference

3 August 2017

1 September 2006

1 reference

Lancet Infectious Diseases

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

589-601

1 reference

3 August 2017

9

1 reference

Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

The need for new antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

The threat from the pink corner

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin for Klebsiella pneumoniae-associated sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Tigecycline: what is it, and where should it be used?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Efflux-mediated resistance to tigecycline (GAR-936) in Pseudomonas aeruginosa PAO1.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Using intrathecal colistin for multidrug resistant shunt infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Intrathecal colistin and sterilization of resistant Pseudomonas aeruginosa shunt infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Successful treatment of multidrug-resistant Acinetobacter baumannii central nervous system infections with colistin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Cure of post-traumatic recurrent multiresistant Gram-negative rod meningitis with intraventricular colistin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Intrathecal colistin for treatment of highly resistant Pseudomonas ventriculitis. Case report and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Toxicity after prolonged (more than four weeks) administration of intravenous colistin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Use of colistin in the treatment of multiple-drug-resistant gram-negative infections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Multidrug-resistant Pseudomonas aeruginosa in Brooklyn, New York: molecular epidemiology and in vitro activity of polymyxin B.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Use of intravenous polymyxin B during continuous venovenous hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Use of high-performance liquid chromatography to study the pharmacokinetics of colistin sulfate in rats following intravenous administration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Safety and tolerability of bolus intravenous colistin in acute respiratory exacerbations in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Intravenous colistin in the treatment of sepsis from multiresistant Gram-negative bacilli in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Four years' experience of intravenous colomycin in an adult cystic fibrosis unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

The pharmacokinetics of colistin in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Pharmacologic and toxicologic studies with the polymyxins. II. Comparative pharmnacologic studies of the sulfate and methanesulfonate salts of polymyxin B and colistin in dogs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Serum and Urine Levels Following Parenteral Administration of Sodium Colistimethate to Normal Individuals

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Pharmacokinetics of inhaled colistin in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

A reassessment of the in-vitro activity of colistin sulphomethate sodium.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Efficacy of colistin versus beta-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Role of Pseudomonas aeruginosa outer membrane protein OprH in polymyxin and gentamicin resistance: isolation of an OprH-deficient mutant by gene replacement techniques

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Regulation of polymyxin resistance and adaptation to low-Mg2+ environments

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Fatty acid alterations and polymyxin B binding by lipopolysaccharides from Pseudomonas aeruginosa adapted to polymyxin B resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Characterization of the lipopolysaccharide from the polymyxin-resistantpmrAmutants ofSalmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Decreased binding of polymyxin by polymyxin-resistant mutants of Salmonella typhimurium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

PhoP-PhoQ activates transcription of pmrAB, encoding a two-component regulatory system involved in Salmonella typhimurium antimicrobial peptide resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Crystal structure of Escherichia coli ArnA (PmrI) decarboxylase domain. A key enzyme for lipid A modification with 4-amino-4-deoxy-L-arabinose and polymyxin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

The Vibrio cholerae ToxR-regulated porin OmpU confers resistance to antimicrobial peptides

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Transcriptional regulation of the 4-amino-4-deoxy-L-arabinose biosynthetic genes in Yersinia pestis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Eradication of early Pseudomonas aeruginosa infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

A ten year review of colomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

The clinical use of colistin in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nosocomial outbreak caused by Salmonella enterica serotype Livingstone producing CTX-M-27 extended-spectrum beta-lactamase in a neonatal unit in Sousse, Tunisia.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Emergence of PER and VEB extended-spectrum beta-lactamases in Acinetobacter baumannii in Belgium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Neurotoxic and nephrotoxic effects of colistin in patients with renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistimethate toxicity. Report of a fatal case in a previously healthy child

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Adverse effects of sodium colistimethate. Manifestations and specific reaction rates during 317 courses of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

APNEA WITH INTRAMUSCULAR COLISTIN THERAPY

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Acute Renal Failure Associated With Sodium Colistimethate Treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nonoliguric renal failure secondary to sodium colistimethate: a report of four cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin: an antimicrobial for the 21st century?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin-associated acute renal failure: revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin-associated acute renal failure: revisited

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Effects of polymyxin B on mammalian urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin interactions with the mammalian urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Cure of multidrug-resistant Acinetobacter baumannii fixation device-related orthopedic infections in two patients with intravenous colistin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Amikacin and colistin for treatment of Acinetobacter baumannii meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Use of Parenteral Colistin for the Treatment of Serious Infection Due to Antimicrobial-Resistant Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Bronchial constriction and inhaled colistin in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nebulized colistin causes chest tightness in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nebulized antibiotic therapy: the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nebulized colistin (polymyxin E) for AIDS-associated Pseudomonas aeruginosa pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

In vitro assessment of colistin's antipseudomonal antimicrobial interactions with other antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2806%2970580-1

7 January 2021

10.1016/S1473-3099(06)70580-1

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

16931410